Full text

Turn on search term navigation

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Simple Summary

Triple-negative breast cancer (TNBC) is a highly aggressive disease. It is marked by a lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Thus, treating TNBC patients with targeted therapy and having a biomarker for therapy response has always been a challenge for medical field experts. TNBC patient tumors have high expression of Annexin A2 (AnxA2) protein and mRNA. Here in this study, we demonstrate that the AnxA2 protein and mRNA highly associate with small extracellular vesicles (sEVs) at the later stages of TNBC which is marked by a better treatment response in TNBC patients. Thus, we introduce sEV-derived AnxA2 protein and mRNA as a combined biomarker for neo-adjuvant chemotherapy response in TNBC.

Abstract

Small extracellular vesicles (sEVs), mainly exosomes, are nanovesicles that shed from the membrane as intraluminal vesicles of the multivesicular bodies, serve as vehicles that carry cargo influential in modulating the tumor microenvironment for the multi-step process of cancer metastasis. Annexin A2 (AnxA2), a calcium(Ca2+)-dependent phospholipid-binding protein, is among sEV cargoes. sEV-derived AnxA2 (sEV-AnxA2) protein is involved in the process of metastasis in triple-negative breast cancer (TNBC). The objective of the current study is to determine whether sEV-AnxA2 protein and/or mRNA could be a useful biomarkers to predict the responsiveness of chemotherapy in TNBC. Removal of Immunoglobulin G (IgG) from the serum as well as using the System Bioscience’s ExoQuick Ultra kit resulted in efficient sEV isolation and detection of sEV-AnxA2 protein and mRNA compared to the ultracentrifugation method. The standardized method was applied to the twenty TNBC patient sera for sEV isolation. High levels of sEV-AnxA2 protein and/or mRNA were associated with stage 3 and above in TNBC. Four patients who responded to neoadjuvant chemotherapy had high expression of AnxA2 protein and/or mRNA in sEVs, while other four who did not respond to chemotherapy had low levels of AnxA2 protein and mRNA in sEVs. Our data suggest that the sEV-AnxA2 protein and mRNA could be a combined predictive biomarker for responsiveness to chemotherapy in aggressive TNBC.

Details

Title
Combination of Small Extracellular Vesicle-Derived Annexin A2 Protein and mRNA as a Potential Predictive Biomarker for Chemotherapy Responsiveness in Aggressive Triple-Negative Breast Cancer
Author
Desai, Priyanka P 1 ; Narra, Kalyani 2 ; James, Johanna D 3 ; Jones, Harlan P 1 ; Tripathi, Amit K 1   VIAFID ORCID Logo  ; Vishwanatha, Jamboor K 1   VIAFID ORCID Logo 

 Department of Microbiology, Immunology and Genetics, University of North Texas Health Science Center, Fort Worth, Texas, TX 76107, USA 
 Department of Internal Medicine, John Peter Smith (JPS) Oncology Infusion Center, Fort Worth, Texas, TX 76104, USA 
 Biosample Repository Facility, Fox Chase Cancer Center, Philadelphia, PA 19111, USA 
First page
212
Publication year
2023
Publication date
2023
Publisher
MDPI AG
e-ISSN
20726694
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2761099454
Copyright
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.